[1] Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms [J]. Nat Rev Mol Cell Biol, 2016,17(7): 451-459.
[2] Bracewell-Milnes T, Saso S, Abdalla H, et al. Metabolomics as a tool to identify biomarkers to predict and improve outcomes in reproductive medicine: a systematic review [J]. Hum Reprod Update, 2017,23(6): 723-736.
[3] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J]. Hum Reprod,2004, 19(1): 41-47.
[4] Dumesic DA, Phan JD, Leung KL, et al. Adipose insulin resistance in normal-weight women with polycystic ovary syndrome [J]. J Clin Endocrinol Metab, 2019,104(6): 2171-2183.
[5] Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome [J]. J Clin Endocrinol Metab,2005, 90(4): 1929-1935.
[6] Ezeh U, Pall M, Mathur R, et al. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome [J]. Hum Reprod,2014, 29(7): 1508-1517.
[7] Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome [J]. Hum Reprod Update, 2009,15(4): 477-488.
[8] Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective [J]. Front Biosci (Elite Ed), 2014, 6:104-119.
[9] Jove M, Pradas Ⅰ, Naudi A, et al. Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome [J]. Oncotarget,2018,9(4): 4522-4536.
[10] Kim JY, Tfayli H, Michaliszyn SF, et al. Impaired lipolysis, diminished fat oxidation, and metabolic inflexibility in obese girls with polycystic ovary syndrome [J]. J Clin Endocrinol Metab, 2018,103(2):546-554.
[11] Van Hoeck Ⅴ, Bols PE, Binelli M, et al. Reduced oocyte and embryo quality in response to elevated non-esterified fatty acid concentrations: a possible pathway to subfertility [J]? Anim Reprod Sci,2014, 149(1-2): 19-29.
[12] Palomba S, Daolio J, La Sala GB. Oocyte competence in women with polycystic ovary syndrome [J]. Trends Endocrinol Metab,2017,28(3): 186-198.
[13] Gu L, Liu H, Gu X, et al. Metabolic control of oocyte development: linking maternal nutrition and reproductive outcomes [J]. Cell Molecular Life Sci, 2015,72(2):251-271.
[14] Niu Z, Lin N, Gu R, et al. Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization [J]. J Clin Endocrinol Metab,2014, 99(11): 2269-2276.
[15] Huang PX, Wei JH, Wei LH. Polycystic ovary syndrome combined with obesity and obese people in IVF-ET in clinical outcomes compared[J]. Chinese Journal of Birth Health and Heredity, 2017,25(9):107-109.(in Chinese)
黄品秀, 韦继红, 韦立红. 多囊卵巢综合征合并肥胖与单纯性肥胖者在IVF-ET中的临床结局相比较[J]. 中国优生与遗传杂志, 2017(9):107-109.
[16] Trenkic M, Popovic J, Bjelica A, et al. Influence of body mass index on in vitro fertilization outcome in women with polycystic ovary syndrome[J]. Med Pregl, 2016, 69(7-8):230-236.
[17] Basuino L, Silveira Jr CF. Human follicular fluid and effects on reproduction [J]. JBRA Assist Reprod, 2016, 20(1): 38-40.
[18] McRae C, Baskind NE, Orsi NM, et al. Metabolic profiling of follicular fluid and plasma from natural cycle in vitro fertilization patients - a pilot study [J]. Fertil Steril, 2012, 98(6): 1449-1457.
[19] Cardozo E, Pavone ME, Hirshfeld-Cytron JE. Metabolic syndrome and oocyte quality [J]. Trends Endocrinol Metab, 2011, 22(3): 103-109.
[20] Ambekar AS, Kelkar DS, Pinto SM, et al. Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development [J]. J Clin Endocrinol Metab, 2015,100(2): 744-753.
[21] Niu Z, Ye Y, Xia L, et al. Follicular fluid cytokine composition and oocyte quality of polycystic ovary syndrome patients with metabolic syndrome undergoing in vitro fertilization [J]. Cytokine, 2017,91: 180-186.
[22] Patil K, Yelamanchi S, Kumar M, et al. Quantitative mass spectrometric analysis to unravel glycoproteomic signature of follicular fluid in women with polycystic ovary syndrome [J]. PLoS One,2019,14(4): e0214742.
[23] Chen X, Lu T, Wang X, et al. Metabolic alterations associated with polycystic ovary syndrome: a UPLC Q-Exactive based metabolomic study [J]. Clin Chim Acta, 2020, 502: 280-286.
[24] Revelli A, Delle Piane L, Casano S, et al. Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics [J]. Reprod Biol Endocrinol, 2009,7: 40-54.
[25] Zeng J, Jiang M, Wu X,et al. SIRT4 is essential for metabolic control and meiotic structure during mouse oocyte maturation [J]. Aging Cell, 2018,17(4): e12789.
[26] Ola SI, Sun QY. Factors influencing the biochemical markers for predicting mammalian oocyte quality [J]. J Reprod Dev, 2012, 58(4): 385-392.
[27] Arya BK, Haq AU, Chaudhury K. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism[J]. Med Hypotheses, 2012, 78(4):475-478.
[28] Rivera R, Chun J. Biological effects of lysophospholipids [J]. Rev Physiol Biochem Pharmacol, 2008,160: 25-46.
[29] Ye X. Lysophospholipid signaling in the function and pathology of the reproductive system [J]. Hum Reprod Update, 2008,14(5): 519-536.
[30] Wallace M, Cottell E, Gibney MJ, et al. An investigation into the relationship between the metabolic profile of follicular fluid, oocyte developmental potential, and implantation outcome [J]. Fertil Steril, 2012,97(5): 1078-1084.
|